Klebsiella oxytoca outbreak in an intensive care unit: a probable link to common insulin vial use.

B. Mete,Y. Aybar Bilir,G. Aygun,M. Yılmaz,S. Urkmez,Y. Dilmen,R. Ozturk

2013-03-01

Anaesthesia and Intensive Care

Abstract:

What problem does this paper attempt to address?

Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies

Xinxin Jiang,Wei Shen,Xiujun Xu,Xiaogang Shen,Yiwen Li,Qiang He

DOI: https://doi.org/10.1007/s10157-017-1484-8

IF: 2.6212

2017-01-01

Clinical and Experimental Nephrology

Abstract:Background The purpose of this study was to conduct a meta-analysis examining the efficacy of cyclophosphamide, cyclosporin, and tacrolimus in treating steroid resistant nephrotic syndrome. Methods Medline, Cochrane, EMBASE, and Google Scholar were searched until May 02, 2017 using the keywords: immunosuppressive therapy, steroid-resistant nephrotic syndrome, cyclophosphamide, cyclosporine A, and tacrolimus. Inclusion criteria were randomized controlled trials (RCTs) including patients with SRNS treated with an immunosuppressive therapy or placebo. Results Seven RCTs were included, and the number of patients ranged from 30 to 131. Conventional pair-wise meta-analysis indicated a higher odds of complete or partial remission with tacrolimus as compared to cyclophosphamide [odds ratio (OR) 4.908, 95% confidence interval (CI) 2.278–10.576, P < 0.001], and cyclophosphamide (OR 0.143, 95% CI 0.028–0.721, P = 0.019) and placebo (OR 0.043, 95% CI 0.012–0.157, P < 0.001) were associated with a lower likelihood of complete or partial remission than cyclosporine. Bayesian analysis indicated that tacrolimus and cyclosporine were the best and the second-best agents for inducing a complete or partial remission (rank probability = 0.53 for tacrolimus and 0.46 for cyclosporine). Conclusion As compared to cyclophosphamide and cyclosporin, tacrolimus is more effective at inducing remission in patients with SRNS.
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome

Agnes Trautmann,Marina Vivarelli,Susan Samuel,Debbie Gipson,Aditi Sinha,Franz Schaefer,Ng Kar Hui,Olivia Boyer,Moin A Saleem,Luciana Feltran,Janina Müller-Deile,Jan Ulrich Becker,Francisco Cano,Hong Xu,Yam Ngo Lim,William Smoyer,Ifeoma Anochie,Koichi Nakanishi,Elisabeth Hodson,Dieter Haffner,

DOI: https://doi.org/10.1007/s00467-020-04519-1

2020-05-07

Pediatric Nephrology

Abstract:Abstract Idiopathic nephrotic syndrome newly affects 1–3 per 100,000 children per year. Approximately 85% of cases show complete remission of proteinuria following glucocorticoid treatment. Patients who do not achieve complete remission within 4–6 weeks of glucocorticoid treatment have steroid-resistant nephrotic syndrome (SRNS). In 10–30% of steroid-resistant patients, mutations in podocyte-associated genes can be detected, whereas an undefined circulating factor of immune origin is assumed in the remaining ones. Diagnosis and management of SRNS is a great challenge due to its heterogeneous etiology, frequent lack of remission by further immunosuppressive treatment, and severe complications including the development of end-stage kidney disease and recurrence after renal transplantation. A team of experts including pediatric nephrologists and renal geneticists from the International Pediatric Nephrology Association (IPNA), a renal pathologist, and an adult nephrologist have now developed comprehensive clinical practice recommendations on the diagnosis and management of SRNS in children. The team performed a systematic literature review on 9 clinically relevant PICO ( P atient or P opulation covered, I ntervention, C omparator, O utcome) questions, formulated recommendations and formally graded them at a consensus meeting, with input from patient representatives and a dietician acting as external advisors and a voting panel of pediatric nephrologists. Research recommendations are also given.

pediatrics,urology & nephrology
New Insights Into Treatment Of Nephrotic Syndrome In Children

Xiaowen Wang,Hong Xu

DOI: https://doi.org/10.1159/000348470

2013-01-01

Contributions to Nephrology

Abstract:Primary nephrotic syndrome (PNS) is the most common glomerular disease seen in children. The pathogenic basis of PNS, in context of witnessed immunological dysfunction and its relationship with slit diaphragm and the podocyte cytoskeleton, has been explored for years. The outcome and management of PNS in children is determined by the response to corticosteroids and the frequency of relapses. The first episode of nephrotic syndrome should be treated adequately, both in terms of dose and duration of steroids, aiming at reducing the risk for subsequent relapses. While patients with steroid-sensitive nephrotic syndrome have a favorable long-term outcome, almost half of them relapse frequently and are at risk of adverse effects of steroids, Immunosuppressive agents are suggested for patients with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. Calcineurin inhibitors are strongly recommended for patients who show resistance to steroids. Rituximab is a new therapy that could be a potential area but still requires further trials. The aim of therapy is to induce and maintain remission of proteinuria while avoiding medication-related adverse effects. Copyright (C) 2013 S. Karger AG, Basel
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

Agnes Trautmann,Olivia Boyer,Elisabeth Hodson,Arvind Bagga,Debbie S. Gipson,Susan Samuel,Jack Wetzels,Khalid Alhasan,Sushmita Banerjee,Rajendra Bhimma,Melvin Bonilla-Felix,Francisco Cano,Martin Christian,Deirdre Hahn,Hee Gyung Kang,Koichi Nakanishi,Hesham Safouh,Howard Trachtman,Hong Xu,Wendy Cook,Marina Vivarelli,Dieter Haffner,Antonia Bouts,Claire Dossier,Francesco Emma,Markus Kemper,Rezan Topaloglu,Aoife Waters,Lutz Thorsten Weber,Alexandra Zurowska,Keisha L. Gibson,Larry Greenbaum,Susan Massengill,David Selewski,Tarak Srivastava,Chia-shi Wang,Scott Wenderfer,Lilian Johnstone,Nicholas Larkins,William Wong,Agnes A. Alba,T. S. Ha,Masoumeh Mokham,Xuhui Zhong,Riku Hamada,Kazumoto Iijima,Kenji Ishikura,Kandai Nozu,Nilzete Bresolin,Nilka De Jesus Gonzalez,Jaime Restrepo,Ifeoma Anochie,Mignon McCulloch,

DOI: https://doi.org/10.1007/s00467-022-05739-3

2022-10-21

Pediatric Nephrology

Abstract:Abstract Idiopathic nephrotic syndrome is the most frequent pediatric glomerular disease, affecting from 1.15 to 16.9 per 100,000 children per year globally. It is characterized by massive proteinuria, hypoalbuminemia, and/or concomitant edema. Approximately 85–90% of patients attain complete remission of proteinuria within 4–6 weeks of treatment with glucocorticoids, and therefore, have steroid-sensitive nephrotic syndrome (SSNS). Among those patients who are steroid sensitive, 70–80% will have at least one relapse during follow-up, and up to 50% of these patients will experience frequent relapses or become dependent on glucocorticoids to maintain remission. The dose and duration of steroid treatment to prolong time between relapses remains a subject of much debate, and patients continue to experience a high prevalence of steroid-related morbidity. Various steroid-sparing immunosuppressive drugs have been used in clinical practice; however, there is marked practice variation in the selection of these drugs and timing of their introduction during the course of the disease. Therefore, international evidence-based clinical practice recommendations (CPRs) are needed to guide clinical practice and reduce practice variation. The International Pediatric Nephrology Association (IPNA) convened a team of experts including pediatric nephrologists, an adult nephrologist, and a patient representative to develop comprehensive CPRs on the diagnosis and management of SSNS in children. After performing a systematic literature review on 12 clinically relevant PICO (Patient or Population covered, Intervention, Comparator, Outcome) questions, recommendations were formulated and formally graded at several virtual consensus meetings. New definitions for treatment outcomes to help guide change of therapy and recommendations for important research questions are given.

pediatrics,urology & nephrology
Duration of initial prednisolone therapy for first episode of childhood nephrotic syndrome based on time to response.

Xiaoshan Tang,Qian Shen,Jia Rao,Jing Chen,Xiaoyan Fang,Zhiqing Zhang,Manpreet Grewal,Tej Mattoo,Hong Xu

DOI: https://doi.org/10.3389/fped.2022.1043285

IF: 3.569

2022-01-01

Frontiers in Pediatrics

Abstract:Background:The duration of initial corticosteroid therapy in newly diagnosed Idiopathic nephrotic syndrome (INS) is about 3 months. Our study was designed to test the feasibility of a shorter duration of corticosteroid therapy in newly diagnosed INS who show a quicker response. Methods:Patients who responded within 10 days (Group A) received 8 weeks of corticosteroid therapy as compared to 12-14 weeks of standard therapy in those who responded between >10 days to 28 days (Group B), and follow up for 52 weeks. The primary endpoint is time to first relapse after treatment completion. (NCT03878914, March 18, 2019). Results:A total of 33 children with INS were enrolled and the follow-up data were analyzed. The clinical and laboratory characteristics of patients in both groups were similar. No significant difference was found in time to first relapse [65(14.5, 159) days for Group A vs. 28(17, 61.5) days for Group B, P = 0.371], the incidence of frequently relapsing nephrotic syndrome [6/18 (33.3%) vs. 5/10(50%), P = 0.644] or requirement for alternative immunosuppressant [4/18 (22.2%) vs. 1/10 (10%), P = 0.769]. Group A received similar corticosteroid dose compare with Group B (3511 ± 2421 mg/m2 vs. 4117 ± 2556 mg/m2, P = 0.524). Frequency and severity of corticosteroid-related complications was similar in both groups. Conclusions:The time to first relapse and the number of relapses per patient were comparable between the two groups. However, more patients in Group A relapsed and the mean total dose of prednisolone for the study period was very similar between the two groups.
Treatment of steroid-resistant, steroid-dependent and relapse nephrotic syndrome in children

XU Hong,LI Guo-min,GONG Yi-nü,LIU Jia-lu

DOI: https://doi.org/10.3877/cma.j.issn.2095-3216.2013.01.003

2013-01-01

Abstract:Primary nephrotic syndrome(PNS) is the most common glomerular disease in children. Treatment of glucocorticoid(GC) for PNS began in 1950'. GC is always the first line drug for PNS since then. 80% to 90% of the children with PNS respond to steroid treatment, among which, 10% to 20% have no relapse, 10% to 20% show infrequent relapse, 40% to 50% present with frequent relapse nephrotic syndrome(FRNS) or steroid dependence nephrotic syndrome(SDNS). 1/3 children with frequent relapse or steroid dependent SDNS show serious side effect because of prolonged and repeated use of GC, such as growth inhibition, hypertension, diabetes, osteoporosis, glaucoma, cataract, and even blindness. 10% to 20% of the children with PNS have steroid resistance nephrotic syndrome(SRNS), and more than half of the patients progress to end-stage renal disease nephrotic syndrome(ESRD) within 10 years. Therefore,we should pay more attention to children with FRNS, SDNS and SRNS. We reviewed most literatures on clinical trial, meta-analysis and guideline in treatment of NS. We summarized treatment of FRNS, SDNS and SRNS in children for pediatrics or children nephrologists.
Corticosteroid therapy for nephrotic syndrome in children.

Deirdre Hahn,Susan M Samuel,Narelle S Willis,Jonathan C Craig,Elisabeth M Hodson

DOI: https://doi.org/10.1002/14651858.CD001533.pub6

IF: 8.4

2022-06-08

Cochrane Database of Systematic Reviews

Abstract:In nephrotic syndrome protein leaks from blood into the urine through the glomeruli resulting in hypoproteinaemia and generalised oedema. While most children with nephrotic syndrome respond to corticosteroids, 80% experience a relapsing course. Corticosteroids have reduced the death rate to around 3%. However, corticosteroids have well recognised potentially serious adverse effects such as obesity, poor growth, hypertension, diabetes mellitus, osteoporosis, and behavioural disturbances. This is an update of a review first published in 2000 and updated in 2002, 2005, 2007, and 2015. The aim of this review was to assess the benefits and harms of different corticosteroid regimens in children with steroid‐sensitive nephrotic syndrome (SSNS). The benefits and harms of therapy were studied in two groups of children 1) children in their initial episode of SSNS, and 2) children who experience a relapsing course of SSNS. We searched the Cochrane Kidney and Transplant Register of Studies up to 30 May 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. Randomised controlled trials (RCTs) performed in children (one to 18 years) in their initial or subsequent episode of SSNS, comparing different durations, total doses or other dose strategies using any corticosteroid agent. Two authors independently assessed risk of bias and extracted data. Results were expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI). In this 2020 review update 16 new included studies were identified providing a total of 48 included studies with 3941 randomised participants. Risk of bias methodology was often poorly performed with only 25 studies and 22 studies respectively assessed to be at low risk for random sequence generation and allocation concealment. Only nine studies (19%) were at low risk of bias for performance (blinding of participants and personnel) and 11 studies were at low risk of detection bias (blinding of outcome assessment); nine of these studies were placebo‐controlled RCTs. Twenty‐two studies (fewer than 50%) were at low risk for attrition bias and 23 studies were at low risk for reporting bias (selective outcome reporting). In seven studies, which evaluated children in their initial episode of SSNS and were at low risk of bias for selection bias, there is little or no difference in the number of children with frequent relapses when comparing two months of prednisone with three months or more (RR 0.99, 95% CI 0.82 to 1.19; 585 participants, 4 studies; I 2 = 0%) or when comparing three months with five to seven months of therapy (RR 0.99, 95% CI 0.74 to 1.33; 376 participants, 3 studies; I 2 = 35%; high certainty evidence). In analyses of eight studies at low risk of selection bias, there is little or no difference in the number of children with any relapse by 12 to 24 months when comparing two months of prednisone with three months or more (RR 0.91, 95% CI 0.78 to 1.06; 637 participants; 5 studies; I 2 = 47%) or when comparing three months with five to seven months of therapy (RR 0.88, 95% CI 0.70 to 1.11; 377 participants, 3 studies; I 2 = 53%). Little or no difference was noted in adverse effects between the different treatment durations. Among children with relapsing SSNS, two small studies showed that time to remission did not differ between prednisone doses of 1 mg/kg compared with the conventional dose of 2 mg/kg (MD 0.71 days, 95% CI ‐0.43 to 1.86; 79 participants) and that the total prednisone dose administered was lower (MD ‐20.60 mg/kg, 95% CI ‐25.65 to ‐15.55; 20 participants). Two studies found little or no difference in the number with relapse at six months when comparing dosing by weight with dosing by surface area (RR 1.03, 95% CI 0.71 to 1.49; 146 participants). One study found a reduced risk of relapse with low daily dosing compared with alternate daily dosing (MD ‐0.90 number of relapses/year, 95% CI ‐1.33 to ‐0.47). Four studies found that in children with frequently relapsing disease, daily prednisone during viral infections compared with alternate‐day prednisone or no treatment reduced the risk of relapse. There are now four well designed studies randomising 823 children which have clearly demonstrated that there is no benefit of prolonging prednisone therapy beyond two to three months in the first episode of SSNS. Small studies in children with relapsing disease have identified no differences in the times to remission using half the conventional induction dose of 2 mg/kg or 60 mg/m 2 . It is imperative that a much larger study be carried out to confirm these findings. Lower dose prednisone therapy administered daily durin -Abstract Truncated-

medicine, general & internal
Reactivation of chronic hepatitis B as acute viral hepatitis.

N. Tassopoulos,G. Papaevangelou,K. Roumeliotoi-Karayannis,R. Purcell

DOI: https://doi.org/10.7326/0003-4819-103-3-481_1

IF: 39.2

1985-09-01

Annals of Internal Medicine

Abstract:Excerpt To the editor: In the June issue, Davis and Hoofnagle (1) present three cases of reactivation of chronic type B hepatitis mimicking acute clinical hepatitis with hepatitis B surface antigen...
Microscopically controlled excision of skin cancer.

J. W. Trimble,R. Schwartz

1982-05-01

American family physician

Abstract:Microscopically controlled excision (Mohs surgery) is a time-proven method of removing skin cancers, especially those with a high rate of recurrence after treatment by standard surgical or radiation techniques. Under the microscope, all lateral and deep margins are checked by sequential horizontal frozen sections. Tumor roots can be extirpated selectively, affording the highest cure rate possible with maximal preservation of normal skin.
Retrospective analysis of pulse methylprednisolone therapy in children with steroid-sensitive relapsing nephrotic syndrome

ZHANG Yan,HUANG Jian-ping,XIAO Hui-jie,DING Jie,YAO Yong,YANG Ji-yun

DOI: https://doi.org/10.3969/j.issn.1000-3606.2007.04.009

2007-01-01

Pediatric Nephrology

Abstract:Objectives To study retrospectively the effectiveness and adverse effects of pulse methylprednisolone therapy (PMT) in children with idiopathic nephrotic syndrome. Methods A retrospective study of 11 cases of steroid-sensitive relapsing nephrotic syndrome which received PMT over a 5-year period(from 2000 to 2004)was performed. All of them had been treated with oral prednisone in similar condition previously. A self-control design was used to compare the effects of PMT with oral prednisone. Results The average age of the 11 cases was 7.5 ± 3.1 years and the average course of disease was 15.1 ± 10.4 months. Relapses were frequent in 8 cases. Ten cases achieved complete remission after the first course of PMT,and the average duration of PMT therapy until remission was 7.4 ± 4.4 days. One case attained complete remission after the second course of PMT. Compared with the effect of oral prednisone previously,7 cases attained complete remission more rapidly. Paired samples t-test was performed to compare the effect of PMT and oral prednisone in 6 cases with very similar conditions,but no statistical difference was detected. During PMT treatment, adverse effects were found in 6 cases. Conclusions Compared with oral prednisone,the superiority of PMT in children with steroid-sensitive nephrotic syndrome had not been confirmed,and some adverse effects have not been eliminated during the treatment. Therefore,we should be very careful when administering PMT in patients. A prospective clinical randomized controlled trial will be necessary to further evaluate the effectiveness of PMT.
A retrospective analysis of clinicopathological features and outcome of secondary steroid resistant nephrotic syndrome

Habib Qaiser,Irshad Bajeer,Sabeeta Khatri,Seema Hashmi,Ali Asghar Lanewala

DOI: https://doi.org/10.47391/jpma.10584

2024-02-11

Journal of the Pakistan Medical Association

Abstract:Objective: To determine the clinico-pathological features and long-term outcome of secondary steroid-resistant nephrotic syndrome treated with steroids and calcineurin inhibitors. Method: The retrospective cohort study was conducted at the Sindh Institute of Urology and Transplant, Karachi, in June and July 2023, and comprised data from January 1, 2008, to December 31, 2020, of children aged 1-18 years who developed steroid resistance after initial sensitivity to steroids with at least 1-year of follow-up. Demographics as well as time taken to secondary steroid response were documented. Renal biopsy of all patients with secondary steroid resistance had been performed. Eventual outcomes after treatment with calcineurin inhibitors based on the degree of proteinuria and serum albumin levels were used to categorise complete remission, partial remission and no response. Kidney function, as determined by estimated glomerular filtration rate, was recorded. Data was analysed using SPSS 22. Results: Of the 1,000 patients who underwent renal biopsy for steroid resistance, 48(4.8%) had idiopathic steroid-resistant nephrotic syndrome; 32(66.7%) males, 16(33.3%) females and median age of 5 years (interquartile range: 4-7.3 years). Median age at diagnosis of nephrotic syndrome was 5 years (interquartile range: 3.6-7.3 years). The median time from nephrotic syndrome to secondary steroid-resistant nephrotic syndrome was 23 months (interquartile range: 8.75-44.5 months). Biopsy results at diagnosis showed that 27(56.3%) had minimal change disease. The mean follow-up time was 6.1±3.2 years. Of the 43(89.5%) patients who received cyclosporin for 1 year, 29(67%) obtained complete remission, 5(12%) attained partial remission and no response was seen in 9(21%) patients. Conclusion: Majority of the children had minimal change disease at the time of diagnosis of secondary steroid-resistant nephrotic syndrome. The long-term response with calcineurin inhibitors was favourable at 1 year. Key Words: Secondary steroid-resistant nephrotic syndrome, Late non-responder nephrotic syndrome, Calcineurin inhibitors, Childhood nephrotic syndrome.

medicine, general & internal, research & experimental
A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome

Bili Zhang,Tao Liu,Wenhong Wang,Xuan Zhang,Shuying Fan,Zhufeng Liu,Zhe Liu,Xia Wu

DOI: https://doi.org/10.1007/s00431-013-2192-3

2013-01-01

European Journal of Pediatrics

Abstract:A prospective study was designed to evaluate the efficacy of azithromycin (AZM) when combined with prednisone therapy compared with prednisone therapy alone in children with primary nephrotic syndrome (PNS) undergoing induction treatment. A prospective randomly controlled clinical trial was conducted. Randomization was performed to select the research subjects who were composed of children with PNS and treated with AZM combined with prednisone (the intervention group) and with prednisone alone (the control group). A total of 211 randomly selected patients with PNS received either AZM combined with prednisone ( n = 106) or prednisone alone ( n = 105) for 6 months. At three months in the follow‐up period, 12 patients were lost to follow up (intervention group, 7; control group, 5), and 6 patients had a transient hypocomplementemia (intervention group, 4 ; control group, 2). AZM was administered at a dose of 10 mg/kg q.d (1 dose per day) for three consecutive days. The median duration before remission was 6 days in the intervention group and 9 days in the control group ( p < 0.0001). Relapse rate differed among the groups at 3 months (11.6 vs. 21.4 %, p = 0.049). No difference in relapse rate was observed between the two groups within 4 to 6 months and at 6 months ( p = 0.168, 0.052). After 4 weeks of treatment, steroid resistance occurred in 1 out of 95 (1.05 %) patients in the intervention group and in 10 out of 98 (10.2 %) patients in the control group ( p = 0.006). After 8 weeks of treatment, no difference was found in steroid resistance between two groups (1/95 vs. 3/98, p = 0.327). During follow-up at 6 months, no difference was exhibited by the two groups on frequent relapse rates ( p = 0.134). Conclusion : If a course of AZM is added to the glucocorticoid-induced treatment among children with PNS, then the sensitivity of prednisone increases. This increase consequently reduces duration to remission and decreases relapse. However, further studies are necessary to confirm these results.
[Cyclophosphamide in idiopathic nephrotic syndrome: Outcome and outlook]

Majda Berkane,Latifa Adarmouch,Mohamed Amine,Aicha Bourrahouat,Imane Ait Sab,Mohamed Sbihi

DOI: https://doi.org/10.1016/j.nephro.2017.03.004

Abstract:Introduction: Cyclophosphamide (CYP) has been used for over 40 years in patients with steroid-sensitive nephrotic syndrome (NSSS) presenting frequent relapses (NSRF) or steroid dependence (NSSD). However, the long-term success of treatment with cyclophosphamide is difficult to predict. The objectives of this study are to determine long-term outcomes of cyclophosphamide and identify the factors associated with sustained remission. Methods: We retrospectively studied the data from 50 patients with idiopathic nephrotic syndrome, treated by oral cyclophosphamide and followed at service of pediatric for more than 8 years for idiopathic nephrotic syndrome and related factors for survival without relapse were evaluated by univariate analysis. Results: The median age at the time of diagnosis was 4.3 years, and median follow-up time was 1.7 years with the median of 8 years at the first use of CYC. Patients had received a median cumulative dose of 168mg/kg. At the end of follow-up, 38% of patients entered into remission after using CYC while 62% failed to respond and further relapses then occur. The median time of stopping corticosteroid therapy was three month. The survival without relapse was respectively 56% (28 patients), 52% (26 patients), 48% (24 patients), and 38% (19 patients), at 6 months, one year, two years and more than two years. In univariate analysis, the survival without relapse was related to the age at the moment of starting the therapy par CYC (the median was 5 months for an age < 8 years and 41 months for an age≥8 years; P=0.049), the type of nephrotic syndrome [36 months for SNRF, 4 months for NSSD and nephrothic syndrome steroid resistant (NSSR); P=0.068], and the histological lesion (6 months for diffuse mesangial proliferation, 2 months for segmental glomerulosclerosis; P=0.009). The age at the moment of diagnosis, the sex and the cumulative dose of CYC did not have significant influence. Conclusion: The results presented in this study suggest the use of oral cyclophosphamide for short period remain second line effective therapy. Further well-designed trials are required to evaluate the efficacy of other steroid-sparing agents.
An algebraic method to solve the radial Schrödinger equation

M. Gadella,L. Lara

DOI: https://doi.org/10.1016/j.camwa.2010.09.023

2010-11-01

Abstract:
Clinical Characteristics and Prognosis Analysis of Children with Idiopathic Nephrotic Syndrome with Different Responses to Steroid Therapy from a Single Center in 20 Years

管娜,丁洁,杨霁云,肖慧捷,姚勇,刘景城,朱赛楠,钟旭辉,王芳

DOI: https://doi.org/10.3760/cma.j.issn.2095-428x.2014.17.004

2014-01-01

Abstract:Objective To analyze the clinical characteristics and prognosis of children diagnosed with idiopathic nephrotic syndrome that showed different responses to steroid treatment.Methods In this study,idiopathic nephrotic syndrome was defined as a 24-hour urinary protein of more than 50 mg/kg body weight as well as a serum albumin concentration of less than 25 g/L.A retrospective study was undertaken to analyze the children who were patients at Peking University First Hospital during Jan.1993 and Dec.2012 and conformed to the above criteria.According to their response to steroid therapy,the children were divided into 3 groups:group that demonstrated remission within 4 weeks after therapy,group that demonstrated remission within 4 to 8 weeks and group that demonstrated resistance to therapy after 8 weeks.Among the children who had more than 1 year of follow up,type of nephrotic syndrome(simple vs nephritic),complications,steroid side effects and serious prognosis (chronic renal failure,renal transplantation or death) were further analyzed.Results Out of total 1 059 children with idiopathic nephrotic syndrome,841 cases had a documented steroid response and were analyzed.Among them,71.7％ (603/841 cases) showed remission within 4 weeks following steroid treatment,while 4.0％ (34/841 cases) showed remission within 4 to 8 weeks and 24.3％ (204/841 cases) showed no remission even after 8 weeks.The average remission time after steroid therapy was(13.2 ± 8.9) d with a median of 10.0 d.Of these children,369 cases had at least 1 year of follow up.In this subset,74.8％ (276/369 cases) went into remission within 4 weeks of steroid therapy,4.9％ (18/369 cases) showed remission within 4 to 8 weeks,and 20.3％ (75/369 cases) were resistant to steroid therapy even after 8 weeks.Onset ages were significantly different(P ＜ 0.01) among the 3 groups [remission within 4 weeks:(5.2 ± 3.3) years old; remission within 4 to 8 weeks:(5.7±3.3) years old ; resistant to therapy after 8 weeks:(6.6 ± 3.8) years old].Simple type nephrotic syndrome was more common in children that responded to steroid therapy within 4 weeks (95.3 ％,263/276 cases) and within 4 to 8 weeks (83.3％,15/18 cases) than in children who were resistant to therapy after 8 weeks(45.3％,34/75 cases).The occurrence rates of acute adrenocortical insufficiency showed a significant difference(P =0.04) among the 3 groups(remission within 4 weeks:4.3％,12/276 cases ; remission within 4 to 8 weeks,2/18 cases:11.1％ ; resistant to therapy after 8 weeks:0).The occurrence rates of poor prognosis were also significantly different(P ＜0.0l) among the 3 groups(remission within 4 weeks:1.4％,4/276 cases ; remission within 4 to 8 weeks:0 ; resistant to therapy after 8 weeks:16.0％,12/75 cases).Conclusions Seventy-one point seven percent of children with idiopathic nephrotic syndrome responded to steroid therapy within 4 weeks.Among children that did not respond within 4 weeks following steroid therapy,14.3％ did respond within 8 weeks,while 85.7％ showed no remission 8 weeks after therapy.The children who responded to steroid therapy within 8 weeks mainly presented as a simple type of nephrotic syndrome and had better prognosis,whereas the children that did not respond within 8 weeks mainly presented with nephritic type nephrotic syndrome and had a poorer prognosis.It should be noted that acute adrenocortical insufficiency was more likely to occur in children that responded to steroid therapy within 4 to 8 weeks.
Prospective clinical randomized controlled trial of pulse methylprednisolone therapy in children with steroid sensitive nephrotic syndrome

Y. Zhang,J. P. Huang,H. J. Xiao,J. Ding,Y. Yao,J. Y. Yang

DOI: https://doi.org/10.3969/j.issn.1000-3606.2010.04.005

2007-01-01

Abstract:Objective A prospective study was designed to further evaluate the efficacy and safety of pulse methylprednisolone therapy (PMT) and to compare its effects with oral prednisone in children with steroid-sensitive nephrotic syndrome.Methods A prospective clinical randomized controlled trial was conducted.Stratified randomization,standard treatment control and open trial design was performed.Children with steroid-sensitive nephrotic syndrome were treated by PMT (PMT group) or oral prednisone (control group).Intention-to-treat analysis was employed to deal the data,while Kaplan-Meier survival analysis,Log Rank test and t-test were used for statistical analysis.Results Thirtyone children were enrolled with only 24 cases suitable for evaluation,including 13 cases in the PMT group and 11 cases in control group.The median remission times were 5 days in PMT group and 8 days in control group,respectively.PMT induced a more rapid remission than oral prednisone (P=0.000 8).More adverse effects were found in PMT group during the first two weeks of treatment,with slower increase of weight and subcutaneous fat thickness over the subsequent 3 months.There was no significant difference in relapse rates between the two groups over the subsequent 3 months.Conclusions Compared with oral prednisone,PMT could induce complete remission more rapidly in children with steroid-sensitive nephrotic syndrome,but some adverse effects might appear during the treatment,with slower increase of weight and subcutaneous fat thickness over the subsequent 3 months.PMT could not prevent relapsing again in the subsequent 3 months.
Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol

Francesca Lugani,Andrea Angeletti,Pietro Ravani,Marina Vivarelli,Manuela Colucci,Gianluca Caridi,Enrico Verrina,Francesco Emma,Gian Marco Ghiggeri

DOI: https://doi.org/10.1136/bmjopen-2021-052450

IF: 3.006

2021-11-01

BMJ Open

Abstract:Introduction Glucocorticoids induce remission in 90% of children with idiopathic nephrotic syndrome (INS). Some become steroid-dependent (SD) and require the addition of steroid sparing drugs such as calcineurin-inhibitors (CNI) or cyclophosphamide, to maintain remission. Considering the toxicity of these drugs, alternative interventions are needed for long-term treatment. The anti-CD20 antibody rituximab has shown promising steroid-sparing properties, with conflicting results in complicated forms of SD-INS. Mycophenolate mofetil (MMF) resulted effective in maintaining free-steroid remission, however, studies are limited to few uncontrolled trials with reported different dose of MMF. Methods and analysis This open-label, two-parallel-arm, superiority controlled randomised clinical trial will enrol children with SD-INS maintained in remission with oral glucocorticoids or CNI. Children and young adults will be randomised to either MMF (1.200 mg/m 2 ) or rituximab (375 mg/m 2 ) infusion. After enrolment, glucocorticoids will be tapered until complete withdrawal. We will enrol 160 children and young adults to detect as significant at the two-sided p value of 0.01 with a power >0.8 a reduction in the risk of 1-year relapse (primary end-point). As secondary endpoints, we will compare the amount of glucocorticoids required to maintain complete remission at 6 and 24 months. Ethics and dissemination The trial was approved by the local ethics boards (Comitato Etico Regione Liguria CER Liguria https://www.portalericerca-liguria.it/ ). We will publish the study results at international scientific meetings. Trial registration numbers NCT004585152 .

medicine, general & internal
Risk Factors for Poor Prognosis of Severe Infection in Children With Idiopathic Nephrotic Syndrome: A Double-Center, Retrospective Study

Hengci Zhang,Shiyuan Qiu,Cheng Zhong,Lin Shi,Jiacheng Li,Tao Zhang,Xiaoping Zhu,Mo Wang

DOI: https://doi.org/10.3389/fped.2021.656215

IF: 3.569

2021-07-14

Frontiers in Pediatrics

Abstract:Background: Infection is the most common complication of Idiopathic Nephrotic Syndrome (INS) and the main cause of INS recurrence, severe infection and even leading to mortality. The purpose of this study was to investigate the risk factors of severe infection in INS children and the clinical parameters influencing prognosis. Methods: Totally 147 children with INS and concomitant infections were enrolled and classified into the severe infection group (SIG) and Non-severe infection group (Non-SIG). The clinical characteristics and auxiliary examination results were compared between the two groups, and the early-warning parameters for severe infection and risk factors for poor prognosis were evaluated. Results: There were 49 patients in the SIG, 98 patients in the Non-SIG. In the SIG, the most common severe infections disease included severe pneumonia (63.6%), severe sepsis (30.6%), septic shock (4.1%). In SIG, Gram-positive bacteria (GPB) were more common, as was respiratory syncytial virus (RSV), and the three most common strains were Pseudomonas aeruginosa, Staphylococcus aureus (SA) and Staphylococcus epidermidis. There were more steroid-resistant nephrotic syndrome and combination of steroids and immunosuppressants in SIG, compared with the Non-SIG ( P = 0.000). Patients in the SIG has lower complement 3 (C3, ≤ 0.55 g/L,) and absolute lymphocyte count (ALC, ≤ 1.5 × 10 9 /L) ( P = 0.004). Logistic regression analysis revealed that the independent risk factors for severe infections were the combined use of immunosuppressants [95% confidence interval (CI):1.569–463.541, P = 0.023], steroid resistance (95% CI: 4.845–2,071.880, P = 0.003), C-reactive protein (CRP) ≥8 mg/L (95% CI: 43.581–959, 935.668, P = 0.001), and infections caused by GPB (95% CI: 27.126–2,118, 452.938, P = 0.002), influenza (95% CI: 2.494–1, 932.221, P = 0.012) and RSV (95% CI: 5.011–24 963.819, P = 0.007). The patients in the SIG were classified into the survival group ( N = 39) and the mortality group ( N = 5). Logistic regression analysis showed that white blood cell count (WBC) >15 × 10 9 /L (95% CI: 1.046–2.844, P = 0.033) was an independent risk factor of poor prognosis for these patients. Conclusions: Resistance to steroids, combined with steroids and IS agents, and GPB infections (especially SA) are high-risk factors for severe infection in children with INS. We should monitor CRP ≥ 8 mg/L, C3 ≤ 0.55 g/L and ALC ≤ 1.5 × 10 9 /L to avoid developing severe infection. Accompanied by an increase in ANC, WBC significantly increased, suggesting a fatal infection.

pediatrics
Risk Factors for Idiopathic Nephrotic Syndrome Relapse in Pediatric Age

Luca Pecoraro,Germana Longo,Mattia Parolin,Enrico Vidal,Nadia Antonucci,Valeria Silecchia,Maria Sangermano,Elisa Benetti

DOI: https://doi.org/10.69097/41-04-2024-04

2024-08-26

Abstract:Introduction. Eighty percent of children with primitive nephrotic syndrome (NS) will have at least one relapse in their life. Specific risk factors could be associated with a higher incidence of relapses and a worse prognosis. This study aims to deepen the demographic and onset-related risk factors in children with known diagnosis of primitive NS attending the Pediatric Nephrology Unit of the University Hospital of Padua. Methods. Observational, descriptive study of all children (1-11 years old) with a known diagnosis of Primitive NS who attended our Pediatric Nephrology Unit between 1 January 2002 and 31 March 2023. Results. 49 patients were involved. 79.5% had at least one episode of NS relapse during their lifetime. 69.4% were classified as frequently relapsing or steroid-dependent NS. The relapse risk factor "non-Western ethnicity" was related to a worse prognosis and steroid-dependent NS classification (p = 0.041). The onset-related risk factor "thrombocytosis" appears to be related to a better prognosis (p = 0.03). Conclusion. The relapse risk factors "non-Western ethnicity" and "thrombocytosis" are characterized by worse and better prognosis, respectively. This evidence could support the follow-up of primitive NS in pediatric age.
Long-term outcomes and influencing factors of idiopathic nephrotic syndrome in children

朱月玲,何雪,王建炳,杨斌斌,李伟,吴芳,刘爱民,傅海东,毛建华

DOI: https://doi.org/10.3760/cma.j.cn441217-20220906-00909

2023-01-01

Abstract:Pediatric idiopathic nephrotic syndrome (INS) is characterized by massive albuminuria, hypoproteinemia, edema and hyperlipidemia, with a long course and high probability of relapse and prolongation. Long-term complications caused by long-term usage of hormones and immunosuppressants in children with INS seriously affect their physical and mental health and quality of life. Most children with steroid-sensitive nephrotic syndrome can be cured before adulthood, while some of them relapse in adulthood. Long-term prognosis of children with steroid-resistant nephrotic syndrome is poor. There have been few studies in China followed the long-term outcomes and its related factors of children with INS over 10 years. The paper reviewed the literatures on the long-term outcomes of children with INS, including renal survival, growth, mental health, learning and work, marriage and fertility, disease recurrence and long-term related complications, to explore the factors related to the poor long-term outcomes of children with INS and to assist in clinical decision-making and follow-up management.

Klebsiella oxytoca outbreak in an intensive care unit: a probable link to common insulin vial use.

Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome

New Insights Into Treatment Of Nephrotic Syndrome In Children

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

Duration of initial prednisolone therapy for first episode of childhood nephrotic syndrome based on time to response.

Treatment of steroid-resistant, steroid-dependent and relapse nephrotic syndrome in children

Corticosteroid therapy for nephrotic syndrome in children.

Reactivation of chronic hepatitis B as acute viral hepatitis.

Microscopically controlled excision of skin cancer.

Retrospective analysis of pulse methylprednisolone therapy in children with steroid-sensitive relapsing nephrotic syndrome

A retrospective analysis of clinicopathological features and outcome of secondary steroid resistant nephrotic syndrome

A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome

[Cyclophosphamide in idiopathic nephrotic syndrome: Outcome and outlook]

An algebraic method to solve the radial Schrödinger equation

Clinical Characteristics and Prognosis Analysis of Children with Idiopathic Nephrotic Syndrome with Different Responses to Steroid Therapy from a Single Center in 20 Years

Prospective clinical randomized controlled trial of pulse methylprednisolone therapy in children with steroid sensitive nephrotic syndrome

Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol

Risk Factors for Poor Prognosis of Severe Infection in Children With Idiopathic Nephrotic Syndrome: A Double-Center, Retrospective Study

Risk Factors for Idiopathic Nephrotic Syndrome Relapse in Pediatric Age

Long-term outcomes and influencing factors of idiopathic nephrotic syndrome in children